Therapeutics
Development and Manufacturing
BARDA is
also funding COVID-19 drug candidates and generic drugs used to treat
hospitalized COVID-19 patients. Last week, BARDA awarded $354 to a
Virginia start-up to make generic drug ingredients and finished
products, $148 million to Janssen to develop antivirals, and $93 million
to Regeneron to develop COVID-19 drugs. Despite this progress, many
have found it a challenge to break through as over a 3-month period,
BARDA has had 2,800 meeting requests and held 250 CoronaWatch meetings.
It is overwhelmed with requests on a range of innovations to address
COVID-19. However, it still has funding and is continuing to get through
all requests and provide feedback before submissions for funding are
made. Also, HHS will work with a team of private industry partners, led
by Phlow, to establish critical generic drug and active pharmaceutical
ingredient (API) manufacturing in the U.S. to mitigate drug shortages.
Industry partners will work with the U.S. government to create a list of
critically needed APIs and finished drug products and implement
advanced manufacturing techniques, such as continuous manufacturing, to
cut down on production costs and waste.
from.... https://www.g2gconsulting.com/updates/health